Results 251 to 260 of about 13,289,951 (302)

The green tea component (-)-epigallocatechin-3-gallate protects against cytokine-induced epithelial barrier damage in intestinal epithelial cells. [PDF]

Front Pharmacol
Rosenthal R, Waesch A, Masete KV, Massarani AS, Schulzke JD, Hering NA.   +5 more
europepmc   +1 more source

Epigallocatechin-3-gallate inhibits the collagen accumulation of oral submucous fibrosis induced by arecoline. [PDF]

Front Pharmacol
Gao G, Lin C, Li R, Xie X, Luo HB.
europepmc   +1 more source

Epigallocatechin-3-gallate at the nanoscale: a new strategy for cancer treatment. [PDF]

Pharm Biol
Sun W, Yang Y, Wang C, Liu M, Wang J, Qiao S, Jiang P, Sun C, Jiang S.   +8 more
europepmc   +1 more source

Research Progress on the Protective Effect of Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG) on the Liver. [PDF]

Nutrients
Zhou F, Deng S, Luo Y, Liu Z, Liu C.
europepmc   +1 more source

Epigallocatechin -3- gallate mitigates diazinon neurotoxicity via suppression of pro-inflammatory genes and upregulation of antioxidant pathways. [PDF]

BMC Neurosci
Onukak CE, Femi-Akinlosotu OM, Obasa AA, Folarin OR, Ajibade TO, Igado OO, Esan OO, Oyagbemi TO, Adeogun AV, Oyagbemi AA, Ola-Davies OE, Omobowale TO, Olopade JO, Oguntibeju OO, Yakubu MA.   +14 more
europepmc   +1 more source

Epigallocatechin-3-Gallate from Green Tea Reduces Vascular Aging and Endothelial Cell Senescence by Modifying Autophagy and Ferroptosis through the Sirtuin 1 Signaling Pathway. [PDF]

ACS Omega
Zhang Y, Wang T, Wang L, Fang Z, Lu T, Chen S, Yan J, Qin C, Shen X, Kang N, Tian L, Cao F.   +11 more
europepmc   +1 more source

Reading Tea Leaves: Epigallocatechin-3-Gallate for Targeting Atrial Fibrosis. [PDF]

Cardiovasc Drugs Ther
Adeleye AG, Chelu MG, Li N.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Topical epigallocatechin‐3‐gallate in the treatment of vitiligo

Australasian Journal of Dermatology, 2021
AbstractObjectiveTo preliminarily assess the efficacy and safety of the topical application of Epigallocatechin‐3‐gallate (EGCG) in treating vitiligo, a 6‐month clinical trial was carried out.MethodPatients were randomly given topical application of EGCG on the assigned lesions, with pimecrolimus being used as the control for twice a day over a 6‐month
Wenting Hu, Lingling Zhang, Fuquan Lin, Jiehao Lei, Miaoni Zhou, AiE Xu   +5 more
openaire   +2 more sources

Epigallocatechin-3-gallate is an inhibitor of Na+,K+-ATPase by favoring the E1 conformation

Biochemical Pharmacology, 2009
Four catechins, epigallocatechin-3-gallate, epigallocatechin, epicatechin-3-gallate, and epicatechin, inhibited activity of the Na+,K+-ATPase. The two galloyl-type catechins were more potent inhibitors, with IC50 values of about 1 μM, than were the other
Hitoshi Takenaka, Kazuhiro Abe, Shunsuke Noguchi   +2 more
exaly   +2 more sources